To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Alopecia Clinical Trial

Official title:

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of KX-826 Tincture for Topical Use in Chinese Adult Female Patients With Androgenetic Alopecia (AGA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06409650
• Other study ID #: KX0826-CN-1004
• Status: Completed
• Phase: Phase 2
• Start date: November 9, 2021
• Est. completion date: December 7, 2023

Study information

• Verified date: May 2024
• Source: Suzhou Kintor Pharmaceutical Inc,
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.

Description:

KX-826 is a new investigational androgen receptor (AR) antagonist for the treatment of female pattern hair loss (androgenetic alopecia). A total of 160 female subjects were randomized to one of four cohorts: 2.5 mg QD, 2.5 mg BID, 5 mg QD, 5mg BID of KX-826 or placebo (BID or QD) for 24 weeks. The primary endpoint of the study is to assess the changes from baseline in non-vellus TAHC （Target Area Hair Counts）at Week 24 in comparison to placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: December 7, 2023
• Est. primary completion date: November 10, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who meet all of the following criteria may be included in this study:

1. Agree to follow the study treatment regimen and visit plan, voluntarily enroll in the study and sign the ICF in writing;

2. Female, = 18 years old;

3. Clinically diagnosed as androgenetic alopecia;

4. Alopecia severity was Ggraded D3-D6 according toon Savin scale;

5. Willing to maintain the same hair style, color and length at each follow-up visit;

6. Have no pregnancy plan and agree to take highly effective contraceptives throughout the study and within 3 months after the last dose. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study drug.

Exclusion Criteria:

• Patients who meet any of the following criteria will be excluded from the study:

1. Medical/surgical history of any uncontrolled serious clinical system diseases, which may affect the safety and efficacy evaluation of the study drug, such as circulatory system, nervous system, hematological system, digestive system (e.g., inflammatory bowel disease), immune system, psychiatric disorders, etc.;

2. Known hair loss disorders other than AGA, such as alopecia areata or diffuse alopecia areata, syphilitic alopecia, cicatricial alopecia, malnutrition, alopecia due to chemotherapy/radiotherapy;

3. Scalp skin diseases that affect the efficacy evaluation, scalp trauma, or other scalp skin lesions requiring topical drug therapy, such as fungal or bacterial infection, severe seborrheic dermatitis, scalp psoriasis, contact dermatitis, severe folliculitis and scalp atrophy;

4. Concomitant diseases that affect hair growth, such as connective tissue disease, inflammatory bowel disease, moderate to severe anemia and significant short-term weight loss;

5. History of hair transplantation or requiring long-term wearing of a wig and hair adhesive during the study treatment;

6. Have used topical drugs for hair loss sites (including corticosteroids, estrogens, etc.) that may affect the efficacy evaluation for = 2 consecutive weeks within 3 months prior to screening;

7. Have used androgen replacement therapy, immunosuppressants and other drugs that may affect the efficacy evaluation within 3 months prior to screening;

8. Have used minoxidil within 6 months prior to screening;

9. Have used spironolactone or cyproterone within 6 months prior to screening;

10. Have received autologous platelet-rich plasma therapy for AGA within 12 months prior to screening;

11. Have received chemotherapy and cytotoxic agents within 12 months prior to screening or have received scalp radiation and/or low-energy laser or scalp surgery for AGA within 12 months prior to screening;

12. Have used other medical shampoos or solutions containing ketoconazole or similar ingredients (e.g., Terzolin) that may affect the efficacy evaluation within 1 month prior to screening;

13. Plan to use any adjuvant or concomitant therapy for the treatment of alopecia throughout the study;

14. Allergic to the study drug or known to be allergic to ingredients of the study drug;

15. History of malignant diseases within 5 years prior to screening;

16. Abnormal and clinically significant findings in physical examination, vital signs, 12-lead ECG, hematology, urinalysis, blood chemistry and thyroid function test at screening, which will affect the efficacy and safety evaluation and study results as judged by the investigator;

17. Positive for any one or more of antibodies of treponema pallidum antibody, human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen or hepatitis C virus antibody;

18. Have undergone major surgery within 3 months prior to screening, or plan to undergo major surgery during the study;

19. Have participated in or being participated in clinical studies of interventional drugs or medical devices within 3 months prior to screening (except for those who participated in non-interventional studies and those who only signed the ICF but did not receive study intervention);

20. History of drug abuse within 1 year prior to screening, or history of drug use or alcohol dependence within 3 months prior to the study;

21. Those who, in the opinion of the investigator, have other conditions that may affect compliance or are not suitable for participation in this study.

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata

Intervention

Drug:
• KX-826 dosed at 2.5mg
2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
• KX-826 dosed at 2.5mg
2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
• KX-826 dosed at 5 mg
5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
• KX-826 dosed at 5 mg
5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
• Matching placebo to KX-826
Placebo applied topically to scalp once daily for 24 weeks
• Matching placebo to KX-826
Placebo applied topically to scalp twice daily for 24 weeks

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital Medical University	Beijing
China	Beijing Tongren Hospital, Capital Medical University	Beijing
China	China-Japan Friendship Hospital	Beijing
China	Peking University First Hospital	Beijing
China	Peking University People's Hospital	Beijing
China	Xiangya Hospital Central South University	Changsha
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing
China	Dermatology Hospital of Southern Medical University	Guangzhou
China	Sir Run Run Shaw Hospital of Zhejiang University School of Medicine	Hangzhou
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou
China	Huashan Hospital, Fudan University	Shanghai
China	Shenzhen People's Hospital	Shenzhen
China	The First Hospital of Hebei Medical University	Shijiazhuang
China	Suining Central Hospital	Suining
China	The Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Koshine Biomedica, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of change in Target Area Hair Counts	Changes from baseline in non-vellus TAHC (Target Area Hair Counts) in comparison to placebo (Non-vellus TAHC is the number of non-vellus hairs within 1 cm² scalp, which usually ranges from 0 to 300. Larger non-vellus TAHC implies thicker hair. In this study, larger change in non-vellus TAHC means better outcome.)	24 weeks
Secondary	Assessment of change in Hair Growth Assessment score	Changes from baseline in HGA (Hair Growth Assessment) score by Principal Investigator and subjects (HGA scale ranged from -3 to 3 and represented decreases from baseline that were substantial, moderate, slight, no change, slight increases, moderate increases, and substantial increases, respectively. HGA improvement was defined as a hair growth assessment score of larger than 0.)	6,12,18 and 24 weeks